Page 18 - Nsclc News Today

A randomized trial found that selpercatinib improved PFS by more than two-fold, but overall survival data remain immature.

In their updated guidelines for patients with small cell lung cancer (SCLC), ASCO has recommended the CDK4/6 inhibitor trilaciclib as a myeloid supportive agent for patients with untreated or previously treated extensive-stage SCLC who are receiving chemotherapy or chemoimmunotherapy.

Experts discuss the current standard treatment options for patients diagnosed with metastatic NSCLC (mNSCLC).

Specialists review specific prognostic factors and biomarkers that help guide treatment selection for patients with metastatic NSCLC (mNSCLC) and discuss if these biomarkers differ from those observed in early-stage NSCLC.

Dear every oncology team...

Medical oncologists discuss the toxicity profile of patritumab deruxtecan and the safety outcomes from HERTHENA-Lung01 in non–small cell lung cancer.

Clinical insights on where patritumab deruxtecan might fit in the treatment paradigm for patients with advanced non–small cell lung cancer.

Zenocutuzumab elicited clinical activity with a tolerable safety profile in patients with advanced non–small cell lung cancer harboring NRG1 fusions, including those with prior afatinib exposure, according to findings from the ongoing, phase 1/2 eNRGy trial.

Aaron Lisberg, MD, provides a look at an upcoming Rapid Readout program looking at the results of the TROPION-Lung01 study investigating Dato-DXd in previously treated patients with advanced/metastatic NSCLC.

Expert oncologist Charu Aggarwal, MD, MPH, shares her excitement for an upcoming program centered on molecular genotyping and its role in the setting of metastatic nonsquamous non–small cell lung cancer management.